CD19 and systemic lupus erythematosus: Additionally, a CARLYSE a phase I study of obecabtagene autoleucel (obe-cel), autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19, with severe, refractory systemic lupus erythematosus (SLE) is under registered trial [21].